Cell Banking Outsourcing Market to Reach US$ 31.8 Billion by 2032 at 12.5% CAGR; North America Leads with 45% Share | Key Players Charles River, Merck KGaA, Cryo-Cell

The Cell Banking Outsourcing Market reached US$ 12.4 billion in 2024 and is expected to reach US$ 31.8 billion by 2032, growing at a CAGR of 12.5% during the forecast period 2025-2032. The market is expanding as biopharmaceutical companies increasingly outsource cell banking services to ensure regulatory compliance, quality assurance, and cost-efficient management of master and working cell banks used in biologics, vaccines, and cell and gene therapy development.

Growth is driven by the rising demand for biologics, monoclonal antibodies, and advanced therapies, along with the increasing complexity of regulatory requirements across global markets. Contract development and manufacturing organizations (CDMOs) are investing in advanced cryopreservation technologies, secure storage infrastructure, and quality-controlled processes to support long-term cell viability and traceability. While challenges such as data security and high validation costs persist, continued outsourcing trends and growing R&D activity in life sciences are strengthening the long-term outlook of the market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cell-banking-outsourcing-market?sai-v

Cell Banking Outsourcing is the practice of contracting specialized service providers to develop, store, test, and manage cell banks for biopharmaceutical research, manufacturing, and regenerative medicine applications.

Key Developments
✅ January 2026: In the United States, biopharmaceutical and cell therapy companies increased outsourcing of master cell bank (MCB) and working cell bank (WCB) services to specialized CDMOs to accelerate biologics, gene therapy, and cell therapy development while ensuring regulatory compliance.

✅ January 2026: In Japan, regenerative medicine companies expanded partnerships with outsourced cell banking service providers to support stem cell, iPSC, and advanced therapy programs under stringent quality and traceability requirements.

✅ January 2026: In Europe, growing clinical pipelines for biologics and advanced therapies drove demand for outsourced cell banking services offering GMP-compliant storage, characterization, and long-term stability testing.

✅ December 2025: In the United States, outsourcing providers enhanced cell banking capabilities by investing in automated cryopreservation, digital sample tracking, and secure biorepository infrastructure to improve scalability and data integrity.

✅ December 2025: In Japan, contract service providers strengthened collaboration with academic research institutes and biotech startups to support early-stage cell line development and commercialization pathways.

✅ December 2025: In Asia-Pacific, increased investment in cell and gene therapy manufacturing boosted demand for outsourced cell banking services to reduce capital expenditure and speed time-to-market.

Mergers & Acquisitions
✅ January 2026: In the United States, a global CDMO acquired a specialized cell banking and biorepository services provider to expand integrated offerings across biologics development and advanced therapy manufacturing.

✅ December 2025: In the United States, a life sciences services company completed the acquisition of a GMP-certified cell banking firm to strengthen capabilities in cell line storage, characterization, and regulatory support.

✅ December 2025: In Europe, a contract development organization acquired a regional cell banking services provider to expand capacity and support growing demand from cell and gene therapy developers.

✅ August 2025: In Asia-Pacific, a biotechnology services company acquired a local cell banking outsourcing firm to enhance regional coverage and support expanding regenerative medicine pipelines.

Key Players
Charles River Laboratories, Inc. | Merck KGaA | Cryo-Cell International Inc. | Clean Biologics | Goodwin Biotechnology Inc. | LifeCell International Pvt. Ltd. | SGS Life Sciences | Others

Key Highlights
Charles River Laboratories, Inc. holds 24.3% share, driven by its comprehensive cell and gene therapy support services, strong biopharmaceutical partnerships, and global laboratory infrastructure.

Merck KGaA holds 20.1% share, supported by its advanced life science tools, cell culture technologies, and strong presence across biopharma manufacturing workflows.

Cryo-Cell International Inc. holds 14.6% share, driven by long-standing expertise in cellular preservation, stem cell banking services, and strong consumer trust.

Clean Biologics holds 12.4% share, leveraging specialized biosafety testing, viral clearance studies, and strong demand from advanced therapy developers.

Goodwin Biotechnology Inc. holds 10.3% share, supported by GMP biologics manufacturing, contract development services, and niche expertise in complex biologics.

LifeCell International Pvt. Ltd. holds 9.1% share, driven by expanding stem cell banking services, growing healthcare awareness, and strong footprint in emerging markets.

SGS Life Sciences holds 7.2% share, supported by testing, inspection, certification services, and regulatory compliance expertise for biologics and cell-based products.

Others account for 2.0% share, comprising regional service providers and niche life science companies offering specialized cell processing, testing, and storage solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cell-banking-outsourcing-market?sai-v

Market Drivers
- Growing demand for cell and gene therapies increasing the need for reliable master and working cell banks.

- Rising preference among biopharmaceutical companies to outsource cell banking to reduce costs and ensure regulatory compliance.

- Increasing complexity of cell-based research and manufacturing requiring specialized infrastructure and expertise.

- Expansion of biologics, biosimilars, and regenerative medicine pipelines worldwide.

- Stringent regulatory requirements for cell line characterization, storage, and documentation supporting professional outsourcing services.

Industry Developments
- Expansion of GMP-compliant cell banking facilities to support clinical and commercial-scale production.

- Strategic partnerships between cell banking service providers, CROs, and biopharmaceutical companies.

- Adoption of advanced cryopreservation, monitoring, and quality control technologies.

- Growth of end-to-end service offerings covering cell line development, characterization, banking, and long-term storage.

- Increased investments in capacity expansion to support rising demand from cell and gene therapy developers.

Regional Insights
North America - 45% share: "Driven by strong biopharmaceutical R&D activity, high number of cell and gene therapy developers, and mature outsourcing ecosystem."

Europe - 27% share: "Supported by robust regulatory frameworks, expanding biologics manufacturing, and growing adoption of outsourced cell banking services."

Asia Pacific - 22% share: "Fueled by rapid growth in biotech research, increasing clinical trial activity, and expanding biomanufacturing infrastructure."

Latin America - 4% share: "Driven by emerging biologics development, improving research capabilities, and gradual adoption of outsourcing models."

Middle East & Africa - 2% share: "Supported by early-stage life sciences investments, academic research growth, and increasing focus on biopharmaceutical development."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cell-banking-outsourcing-market?sai-v

Key Segments

By Bank Type
Master cell banking represents a critical segment, driven by its role in establishing a well-characterized, long-term source of cells for biopharmaceutical production and research. Working cell banking holds a significant share, supported by routine manufacturing, quality control, and scalability requirements. Viral cell banking is growing steadily, driven by increasing demand for vaccine production, gene therapy, and viral vector-based therapeutics.

By Cell Type
Stem cell banking accounts for a major share, driven by regenerative medicine research and therapeutic applications. Cord stem cell banking represents a significant segment, supported by rising awareness of newborn stem cell preservation. Embryonic stem cell banking contributes through advanced research applications, though growth is moderated by ethical and regulatory considerations. Adult stem cell banking is expanding steadily, driven by clinical research and autologous therapy development. Dental stem cell banking is emerging, supported by minimally invasive collection and potential regenerative uses. Induced pluripotent stem cell banking is gaining strong traction, driven by advances in reprogramming technologies and personalized medicine research. Non-stem cell banking contributes through storage of specialized cell lines used in diagnostics, research, and production.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.